| University of California, San Diego | Armin Blesch | Simplification of Excipient Solution for Implanting Candidate Human H9-scNSC Cell Line for Spinal Cord Injury |
$180,000 |
| Stanford University | Dr. Helen M Blau | Stimulating endogenous muscle stem cells to counter muscle wasting |
$237,060 |
| University of California, Irvine | Dr. Brian J. Cummings | Human neural stem cell (hNSC) derived exosomes vs CSC14 hNSCs for the treatment of traumatic brain injury (TBI) |
$202,667 |
| University of California, Berkeley | Kevin E. Healy | Safety “Clinical Trial” of the Cardiac Liability of COVID19 Polytherapy |
$224,500 |
| University of California, Los Angeles | Dr. Caroline Y. Kuo | Evaluation of Gene Therapy Approaches for Autosomal Recessive Hyper IgE Syndrome Due to Mutations in DOCK8 |
$234,000 |
| Neurona Therapeutics | Dr. Cory R Nicholas | Global gene expression profiling of single inhibitory neurons derived from human stem cells |
$202,500 |
| Stanford University | Professor Hiromitsu Nakauchi | Using metabolic pausing for maintaining stable and high-quality pluripotent stem cells |
$208,422 |
| Aspen Neuroscience | Dr. Andres Bratt-Leal | Autologous therapy for Parkinson’s disease: single cell RNAseq for in depth characterization of transplanted cells |
$177,579 |
